Skip to search formSkip to main contentSkip to account menu

denosumab

Known as: Denosumab [Chemical/Ingredient], Densosumab 
A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity… 
National Institutes of Health

Related topics

Related topics

11 relations
1 ML denosumab 60 MG/ML Prefilled Syringe [Prolia]1.7 ML denosumab 70 MG/ML Injection [Xgeva]In BloodNCIt Antineoplastic Agent Terminology

Narrower (3)

AMG 162ProliaXgeva

Broader (1)

Bone Density Conservation Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Emerging therapies in bone metastasis.
2015
2015
Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis
In 2014, two phase II clinical studies reported rapid, impressive increases in BMD in women with low bone mass who were treated… 
2014
2014
MRI osteitis predicts cartilage damage at the wrist in RA: a three-year prospective 3T MRI study examining cartilage damage
IntroductionCartilage damage impacts on patient disability in rheumatoid arthritis (RA). The aims of this magnetic resonance… 
2014
2014
Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study
ObjectiveThis study aims to evaluate patient perceptions of subcutaneous denosumab or oral alendronate in postmenopausal women… 
Review
2013
Review
2013
A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
2013
2013
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
SummaryThe objective was to undertake a health economic analysis of denosumab for the treatment of osteoporosis in women from the… 
2013
2013
Nouvelles thérapeutiques dans le cancer de la prostate résistant à la castration : panorama des études pivotales et nouveaux schémas thérapeutiques à venir
Review
2013
Review
2013
Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey
Review
2012
Review
2012
The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function… 
2008
2008
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)